D010281Chemicals & DrugsD06.472.699.590D12.644.548.58711230.983436Parathyroid HormoneFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentDivisionvivo:hrJobTitleHR job titleInformation Resourcevivo:orcidIdORCID idPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersontrue1ProfessorProfessorMarkCohenMark Cohen41.87352120000000-87.66713820000000349059Cohen, MarkProfessor30975497Claflin J, Dhir A, Espinosa NM, Antunez AG, Cohen MS, Gauger PG, Miller BS, Hughes DTSurgeryIntraoperative parathyroid hormone levels =40 pg/mL are associated with the lowest persistence rates after parathyroidectomy for primary hyperparathyroidism. Surgery. 2019 07; 166(1):50-54.Surgery2019-04-08T00:00:002019Intraoperative parathyroid hormone levels =40 pg/mL are associated with the lowest persistence rates after parathyroidectomy for primary hyperparathyroidism.true1ProfessorProfessorPathologyRobertDeCresceRobert DeCresce349236DeCresce, RobertProfessorRyanRossRyan Ross349534Ross, RyanAssociate ProfessorAmarjitVirdiAmarjit Virdi349707Virdi, AmarjitProfessor5Associate Professor4Professor1.037840.015284711research area of0.776640.015542223subject area for26514840Ross RD, Mashiatulla M, Robling AG, Miller LM, Sumner DRCalcified tissue internationalBone Matrix Composition Following PTH Treatment is Not Dependent on Sclerostin Status. Calcif Tissue Int. 2016 Feb; 98(2):149-57.Calcif Tissue Int2015-10-29T00:00:002015Bone Matrix Composition Following PTH Treatment is Not Dependent on Sclerostin Status.Orthopedic SurgeryAnatomy and Cell BiologyRush University, Rush Medical CollegeDale (Rick)SumnerDale (Rick) Sumner41.87328300000000-87.66936330000000349028Sumner, Dale (Rick)0000-0001-9575-3862Professor32768241Ryder CY, Jarocki A, McNeely MM, Currey E, Miller BS, Cohen MS, Gauger PG, Hughes DTSurgeryEarly biochemical response to parathyroidectomy for primary hyperparathyroidism and its predictive value for recurrent hypercalcemia and recurrent primary hyperparathyroidism. Surgery. 2021 01; 169(1):120-125.Surgery2020-08-05T00:00:002020Early biochemical response to parathyroidectomy for primary hyperparathyroidism and its predictive value for recurrent hypercalcemia and recurrent primary hyperparathyroidism.true1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessor27464610Keutgen XM, Nilubol N, Agarwal S, Welch J, Cochran C, Marx SJ, Weinstein LS, Simonds WF, Kebebew EAnnals of surgical oncologyReoperative Surgery in Patients with Multiple Endocrine Neoplasia Type 1 Associated Primary Hyperparathyroidism. Ann Surg Oncol. 2016 12; 23(Suppl 5):701-707.Ann Surg Oncol2016-07-27T00:00:002016Reoperative Surgery in Patients with Multiple Endocrine Neoplasia Type 1 Associated Primary Hyperparathyroidism.24293098Ross RD, Hamilton JL, Wilson BM, Sumner DR, Virdi ASCurrent osteoporosis reportsPharmacologic augmentation of implant fixation in osteopenic bone. Curr Osteoporos Rep. 2014 Mar; 12(1):55-64.Curr Osteoporos Rep2014-03-01T00:00:002014Pharmacologic augmentation of implant fixation in osteopenic bone.